Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Cladribine (also known as 2-CdA, 2-chlorodeoxyadenosine; Leustatin; Leustat; Leustatine), a purine nucleoside antimetabolite analogue and an approved medication used for treating hairy cell leukemia and B-cell chronic lymphocytic leukemia, is an adenosine deaminase inhibitor for U266, RPMI8226, and MM1.S cells with IC50s of approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively. It is a well-known purine nucleoside analog that exhibits unique anti-lymphoma-proliferative activity against diseases like hairy cell leukemia (HCL). Cladribine exhibited dose-dependent inhibition of cell proliferation in U266, RPMI8226, and MM1.S cells, with IC50 values of 2.43, 0.75, and 0.18 μmol/L, in that order.
Targets |
Adenosine deaminase (MM1.S cells) ( IC50 = 0.18 μM )
Adenosine deaminase (RPMI8226 cells) ( IC50 = 0.75 μM ) Adenosine deaminase (U266 cells) ( IC50 = 2.43 μM ) |
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
The viability of the cells is assessed using the non-radioactive cell proliferation kit. To summarize, 0.1 mL of complete medium (5% FBS) is used as a control, or 0.1 mL of the same medium containing multiple doses of cladribine, is added to 96-well plates, and the cells are incubated for 72 hours. Reduction of MTS is used to calculate the percentages of surviving cells from each group in comparison to controls, which is defined as 100% survival, after reading all wells at 490 nm using a micro-plate reader.
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C10H12CLN5O3
|
---|---|
Molecular Weight |
285.69
|
Exact Mass |
285.06
|
Elemental Analysis |
C, 42.04; H, 4.23; Cl, 12.41; N, 24.51; O, 16.80
|
CAS # |
4291-63-8
|
Appearance |
Solid powder
|
SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
|
InChi Key |
PTOAARAWEBMLNO-KVQBGUIXSA-N
|
InChi Code |
InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
|
Chemical Name |
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
|
Synonyms |
2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA; 2-CdA, 2-chlorodeoxyadenosine; Cladribina. Trade name: Leustatin; Leustat; Leustatine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
5% DMSO+ 30% PEG 300+ 1% Tween 80+ H2O: 10mg/mL (35.00mM) (Please use freshly prepared in vivo formulations for optimal results.)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5003 mL | 17.5015 mL | 35.0030 mL | |
5 mM | 0.7001 mL | 3.5003 mL | 7.0006 mL | |
10 mM | 0.3500 mL | 1.7501 mL | 3.5003 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04239820 | Active Recruiting |
Radiation: Imaging | Multiple Sclerosis | Turku University Hospital | January 10, 2020 | N/A |
NCT04640818 | Active Recruiting |
Drug: Cladribine Oral Tablet Drug: Rituximab |
Multiple Sclerosis | Claudio Gobbi | December 17, 2020 | N/A |
NCT03933215 | Active Recruiting |
Drug: Cladribine Tablets | Multiple Sclerosis | EMD Serono Research &May 21, 2019 |
N/A |
|
NCT03933202 | Active Recruiting |
Drug: Cladribine Tablets | Multiple Sclerosis | EMD Serono Research & Development Institute, Inc. |
July 22, 2019 | N/A |
NCT04239820 | Active Recruiting |
Radiation: Imaging | Multiple Sclerosis | Turku University Hospital | January 10, 2020 | N/A |